{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:41Z","timestamp":1782337301277,"version":"3.54.5"},"reference-count":264,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","award":["24ZXZSSS00230"],"award-info":[{"award-number":["24ZXZSSS00230"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["23JCQNJC01600"],"award-info":[{"award-number":["23JCQNJC01600"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,430,010"],"award-info":[{"award-number":["82,430,010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101853"],"award-info":[{"award-number":["82101853"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2023-I2M-QJ-015"],"award-info":[{"award-number":["2023-I2M-QJ-015"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2024-I2M-ZH-016"],"award-info":[{"award-number":["2024-I2M-ZH-016"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117332","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T06:51:14Z","timestamp":1757659874000},"page":"117332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy"],"prefix":"10.1016","volume":"242","author":[{"given":"Yixuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-5781","authenticated-orcid":false,"given":"Wenwei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0005","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1128\/JVI.74.8.3494-3504.2000","article-title":"Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein","volume":"74","author":"Ogston","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2025.117332_b0010","doi-asserted-by":"crossref","first-page":"15044","DOI":"10.1038\/mtm.2015.44","article-title":"Vaccinia virus as a subhelper for AAV replication and packaging","volume":"2","author":"Moore","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr. Gene Ther."},{"issue":"3685","key":"10.1016\/j.bcp.2025.117332_b0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/JVI.72.1.309-319.1998","article-title":"Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2","volume":"72","author":"Rutledge","year":"1998","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/jb.90.1.271-274.1965","article-title":"Association of 20-Millimicron Particles with Adenoviruses","volume":"90","author":"Melnick","year":"1965","journal-title":"J. Bacteriol."},{"issue":"5033","key":"10.1016\/j.bcp.2025.117332_b0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/210331a0","article-title":"Small deoxyribonucleic acid-containing viruses (picodnavirus group)","volume":"210","author":"Mayor","year":"1966","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0042-6822(84)90272-1","article-title":"Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus","volume":"134","author":"Georg-Fries","year":"1984","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0055","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0042-6822(84)90271-X","article-title":"Characterization of the DNA of a defective human parvovirus isolated from a genital site","volume":"134","author":"Bantel-Schaal","year":"1984","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1128\/JVI.73.2.939-947.1999","article-title":"Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses","volume":"73","author":"Bantel-Schaal","year":"1999","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0070","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0075","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bcp.2025.117332_b0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.omtm.2020.06.003","article-title":"Development of AAV variants with human hepatocyte tropism and neutralizing antibody escape capacity","volume":"18","author":"Pei","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0095","doi-asserted-by":"crossref","first-page":"G296","DOI":"10.1152\/ajpgi.00562.2010","article-title":"Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis","volume":"302","author":"Polyak","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"7\u20138","key":"10.1016\/j.bcp.2025.117332_b0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","article-title":"AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy","volume":"26","author":"Pattali","year":"2019","journal-title":"Gene Ther."},{"issue":"6469","key":"10.1016\/j.bcp.2025.117332_b0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design","volume":"366","author":"Ogden","year":"2019","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.bcp.2025.117332_b0110","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.gt.3301841","article-title":"IL-10 gene therapy prevents TNBS-induced colitis","volume":"9","author":"Lindsay","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1028380","article-title":"Adeno-associated virus vector intraperitoneal injection induces colonic mucosa and submucosa transduction and alters the diversity and composition of the faecal microbiota in rats","volume":"12","author":"Ma","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr. Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1566523054065011","article-title":"Mechanisms of adeno-associated virus genome encapsidation","volume":"5","author":"Timpe","year":"2005","journal-title":"Curr. Gene Ther."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0130","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: virus versus vector","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0140","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.gt.3300680","article-title":"Adeno-associated virus vectors can be efficiently produced without helper virus","volume":"5","author":"Matsushita","year":"1998","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0145","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)","volume":"59","author":"Erles","year":"1999","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2025.117332_b0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coviro.2014.05.007","article-title":"Parvovirus glycan interactions","volume":"7","author":"Huang","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0155","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chom.2011.10.014","article-title":"Adeno-Associated virus 2 infection requires endocytosis through the CLIC\/GEEC pathway","volume":"10","author":"Nonnenmacher","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0160","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/JVI.74.6.2777-2785.2000","article-title":"Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors","volume":"74","author":"Bartlett","year":"2000","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bcp.2025.117332_b0170","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV Vectors Advances and Applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Molecul. Therapy"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.joim.2024.01.001","article-title":"Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency","volume":"22","author":"Meng","year":"2024","journal-title":"J. Integr. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.joim.2022.10.003","article-title":"The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus serotype 2 vectors both in vitro and in vivo","volume":"21","author":"Xie","year":"2023","journal-title":"J. Integr. Med."},{"issue":"18","key":"10.1016\/j.bcp.2025.117332_b0185","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1089\/hum.1998.9.18-2745","article-title":"Novel tools for production and purification of recombinant adenoassociated virus vectors","volume":"9","author":"Grimm","year":"1998","journal-title":"Hum. Gene Ther."},{"issue":"16","key":"10.1016\/j.bcp.2025.117332_b0190","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1089\/hum.1998.9.16-2353","article-title":"High-titer adeno-associated viral vectors from a Rep\/Cap cell line and hybrid shuttle virus","volume":"9","author":"Gao","year":"1998","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0195","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/hum.2009.004","article-title":"Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells","volume":"20","author":"Thomas","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0200","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/bit.23028","article-title":"Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals","volume":"108","author":"Marek","year":"2011","journal-title":"Biotechnol. Bioeng."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0205","doi-asserted-by":"crossref","first-page":"8780","DOI":"10.1128\/jvi.71.11.8780-8789.1997","article-title":"Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap","volume":"71","author":"Conway","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2025.117332_b0210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-386509-0.00012-0","article-title":"Adeno-associated virus vectorology, manufacturing, and clinical applications","volume":"507","author":"Grieger","year":"2012","journal-title":"Methods Enzymol."},{"issue":"24","key":"10.1016\/j.bcp.2025.117332_b0215","doi-asserted-by":"crossref","first-page":"13150","DOI":"10.1128\/JVI.01415-13","article-title":"Comparative analysis of adeno-associated virus capsid stability and dynamics","volume":"87","author":"Rayaprolu","year":"2013","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0220","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/1566523034578131","article-title":"Evaluation of risks related to the use of adeno-associated virus-based vectors","volume":"3","author":"Tenenbaum","year":"2003","journal-title":"Curr. Gene Ther."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jviromet.2009.03.020","article-title":"Adeno-associated virus capsid serotype identification: analytical methods development and application","volume":"159","author":"Van Vliet","year":"2009","journal-title":"J. Virol. Methods"},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0240","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of InT\u00e1Vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0245","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a prospective Natural history Cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"issue":"10097","key":"10.1016\/j.bcp.2025.117332_b0250","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.bcp.2025.117332_b0255","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/humc.2016.29010.ind","article-title":"Investor outlook: rising from the ashes; GSK's European approval of strimvelis for ADA-SCID","volume":"27","author":"Schimmer","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0265","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nbt0817-691","article-title":"First approval in sight for Novartis' CAR-T therapy after panel vote","volume":"35","author":"Sheridan","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0270","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0275","unstructured":"CADTH Common Drug Reviews, in Clinical Review Report: Voretigene Neparvovec (Luxturna): (Novartis Pharmaceuticals Canada Inc.): Indication: Vision loss, inherited retinal dystrophy. 2021, Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2021 Canadian Agency for Drugs and Technologies in Health.: Ottawa (ON)."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0280","article-title":"Gene therapy for Spinal Muscular Atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0285","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1096\/fj.201700982R","article-title":"The rapidly evolving state of gene therapy","volume":"32","author":"Gruntman","year":"2018","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0290","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMra032207","article-title":"Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency","volume":"350","author":"McCormack","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5235","key":"10.1016\/j.bcp.2025.117332_b0295","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"224","key":"10.1016\/j.bcp.2025.117332_b0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0305","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbrc.2017.07.041","article-title":"A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models","volume":"491","author":"Zhang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ng0696-175","article-title":"A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast","volume":"13","author":"Laporte","year":"1996","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0315","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","article-title":"Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs","volume":"25","author":"Mack","year":"2017","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0320","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1523\/JNEUROSCI.10-12-03801.1990","article-title":"Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey","volume":"10","author":"Koliatsos","year":"1990","journal-title":"J. Neurosci."},{"issue":"220","key":"10.1016\/j.bcp.2025.117332_b0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007523","article-title":"Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy","volume":"6","author":"Childers","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0330","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6","article-title":"Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease","volume":"48","author":"Leone","year":"2000","journal-title":"Ann. Neurol."},{"issue":"6134","key":"10.1016\/j.bcp.2025.117332_b0335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/329065a0","article-title":"Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor","volume":"329","author":"Fischer","year":"1987","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0340","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2025.03.030","article-title":"Recent developments in gene therapy for Parkinson's disease","volume":"33","author":"Szunyogh","year":"2025","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5214\/ans.0972-7531.1017209","article-title":"The current status of gene therapy for Parkinson's disease","volume":"17","author":"Muramatsu","year":"2010","journal-title":"Ann. Neurosci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0350","first-page":"948","article-title":"Future of gene therapy for Parkinson's disease","volume":"44","author":"Mochizuki","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0355","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1097-4547(19990701)57:1<137::AID-JNR15>3.0.CO;2-D","article-title":"Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines","volume":"57","author":"Mi","year":"1999","journal-title":"J. Neurosci. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0360","first-page":"1589","article-title":"Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation","volume":"12","author":"During","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0365","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-Associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu. Rev. Med."},{"issue":"23","key":"10.1016\/j.bcp.2025.117332_b0370","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0375","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.bcp.2025.117332_b0380","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bcp.2025.117332_b0385","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.bcp.2025.117332_b0390","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0395","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/13543784.2022.2138742","article-title":"Early stage clinical trials for the treatment of hemophilia A","volume":"31","author":"Guzzardo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0400","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2025.117332_b0405","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jvh.13934","article-title":"The complex, confusing and poorly understood immune responses to AAV-mediated gene transfer in haemophilia-is more or less immunosuppression required?","volume":"31","author":"Tuddenham","year":"2024","journal-title":"J. Viral Hepat."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0410","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bcp.2025.117332_b0415","article-title":"Retinitis pigmentosa: from pathomolecular mechanisms to therapeutic strategies","volume":"60","author":"Vingolo","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0420","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","article-title":"Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: a comprehensive review","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121558","article-title":"Neuronal p58(IPK) protects retinal ganglion cells independently of macrophage\/microglia activation in ocular hypertension","volume":"12","author":"McLaughlin","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0430","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/jvi.70.11.8098-8108.1996","article-title":"Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector","volume":"70","author":"Xiao","year":"1996","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0435","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0440","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4155\/tde.12.63","article-title":"Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector","volume":"3","author":"Xiao","year":"2012","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0445","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/mt.2015.150","article-title":"Gene therapy restores hair cell stereocilia morphology in inner ears of deaf whirler mice","volume":"24","author":"Chien","year":"2016","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0450","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.1038\/s41598-017-09805-x","article-title":"Intravenous rAAV2\/9 injection for murine cochlear gene delivery","volume":"7","author":"Shibata","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0455","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/gt.2010.175","article-title":"Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear","volume":"18","author":"Kilpatrick","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0460","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-Mediated invivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcp.2025.117332_b0465","doi-asserted-by":"crossref","first-page":"45524","DOI":"10.1038\/srep45524","article-title":"Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction","volume":"7","author":"Suzuki","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117332_b0470","article-title":"Association between serum antinuclear antibody and rheumatoid arthritis","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.bcp.2025.117332_b0475","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0480","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrrheum.2016.147","article-title":"Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles","volume":"12","author":"Coutant","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2025.117332_b0485","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fimmu.2015.00370","article-title":"The many alternative faces of macrophage activation","volume":"6","author":"Hume","year":"2015","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0490","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1756-185X.12132","article-title":"Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis","volume":"16","author":"Azizi","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0495","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/ar4325","article-title":"Role of neutrophils in systemic autoimmune diseases","volume":"15","author":"Kaplan","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0500","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the initiation and evolution of rheumatoid arthritis","volume":"9","author":"Holers","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0505","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.addr.2006.01.009","article-title":"Gene therapeutic approaches-transfer in vivo","volume":"58","author":"Evans","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2025.117332_b0510","article-title":"Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0515","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/annrheumdis-2016-210630","article-title":"IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro","volume":"76","author":"Boutet","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130612","article-title":"Preclinical potency and biodistribution studies of an AAV 5 vector expressing human interferon-\u03b2 (ART-I02) for local treatment of patients with rheumatoid arthritis","volume":"10","author":"Aalbers","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0525","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","article-title":"PD-L1","volume":"71","author":"Kythreotou","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcp.2025.117332_b0530","article-title":"Secreted PD-L1 alleviates inflammatory arthritis in mice through local and systemic AAV gene therapy","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117332_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155808","article-title":"Multifaceted roles of IL-38 in inflammation and cancer","volume":"151","author":"Diaz-Barreiro","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.bcp.2025.117332_b0540","first-page":"386","article-title":"IL-38: a new factor in rheumatoid arthritis","volume":"4","author":"Takenaka","year":"2015","journal-title":"Biochem. Biophys. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0545","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1002\/iid3.991","article-title":"The emerging role of IL-38 in diseases: a comprehensive review","volume":"11","author":"Chen","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0550","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1186\/ar1165","article-title":"Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis","volume":"6","author":"van Holten","year":"2004","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0555","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A","article-title":"Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy","volume":"42","author":"Triantaphyllopoulos","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0560","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/rheumatology\/38.4.362","article-title":"The effects of interferon beta treatment on arthritis","volume":"38","author":"Tak","year":"1999","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0565","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2003.020347","article-title":"A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0570","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.joca.2021.09.013","article-title":"Administration of an adeno-associated viral vector expressing interferon-\u03b2 in patients with inflammatory hand arthritis, results of a phase I\/II study","volume":"30","author":"Vrouwe","year":"2022","journal-title":"Osteoarthr. Cartil."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0575","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0952-7915(00)00167-9","article-title":"Novel, non-antigen-specific therapeutic approaches to autoimmune\/inflammatory diseases","volume":"12","author":"Illei","year":"2000","journal-title":"Curr. Opin. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0580","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jgm.1053","article-title":"Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis","volume":"9","author":"Khoury","year":"2007","journal-title":"J. Gene Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0585","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3899\/jrheum.090817","article-title":"Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1\/2 Study","volume":"37","author":"Mease","year":"2010","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0590","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/ard.2008.089375","article-title":"Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study","volume":"68","author":"Mease","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0595","article-title":"Infliximab for the treatment of rheumatoid arthritis","volume":"2002","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2025.117332_b0600","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2025.117332_b0605","unstructured":"Justiz Vaillant, A.A., A. Goyal, and M. Varacallo, Systemic Lupus Erythematosus, in StatPearls. 2024, StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.: Treasure Island (FL)."},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0610","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0615","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0620","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.1400977","article-title":"IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells","volume":"193","author":"Mizui","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.117332_b0625","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.omtm.2018.10.007","article-title":"Alpha 1 antitrypsin gene therapy extends the lifespan of lupus-prone mice","volume":"11","author":"Elshikha","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156583","article-title":"Alpha 1 antitrypsin inhibits dendritic cell activation and attenuates nephritis in a mouse model of lupus","volume":"11","author":"Elshikha","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117332_b0635","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1479-5876-9-21","article-title":"Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model","volume":"9","author":"Grimstein","year":"2011","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0640","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000438633","article-title":"TIPE2 alleviates systemic lupus erythematosus through regulating macrophage polarization","volume":"38","author":"Li","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2025.117332_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110514","article-title":"Research progress of TIPE2 in immune-related diseases","volume":"121","author":"Gao","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117332_b0650","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.gt.3302015","article-title":"Gene- and cell-based therapeutics for type I diabetes mellitus","volume":"10","author":"Bottino","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2025.117332_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101809","article-title":"The beta cell-immune cell interface in type 1 diabetes (T1D)","volume":"78","author":"James","year":"2023","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0660","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.2337\/db13-0669","article-title":"beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0665","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/gt.2014.45","article-title":"Expression of IL-2 in \u03b2 cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabetes through activation of FoxP3-positive regulatory T cells","volume":"21","author":"Flores","year":"2014","journal-title":"Gene Ther."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b0670","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jir.2021.0147","article-title":"Interleukin-35: structure, function and its impact on immune-related diseases","volume":"41","author":"Ye","year":"2021","journal-title":"J. Interferon Cytokine Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0675","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1530\/EJE-17-0080","article-title":"Mechanisms in endocrinology: towards the clinical translation of stem cell therapy for type 1 diabetes","volume":"177","author":"Espes","year":"2017","journal-title":"Eur. J. Endocrinol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0680","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc16-2121","article-title":"Increased interleukin-35 levels in patients with type 1 diabetes with remaining C-peptide","volume":"40","author":"Espes","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0685","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/eji.201646493","article-title":"beta-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice","volume":"47","author":"Manzoor","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0690","doi-asserted-by":"crossref","first-page":"E1043","DOI":"10.1152\/ajpendo.00570.2014","article-title":"Insulin-independent reversal of type 1 diabetes in nonobese diabetic mice with brown adipose tissue transplant","volume":"308","author":"Gunawardana","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0695","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.molmet.2017.05.007","article-title":"AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice","volume":"6","author":"Mallol","year":"2017","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168981","article-title":"Human Alpha-1-Antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury","volume":"12","author":"Maicas","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0705","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091341","article-title":"Alpha-1-antitrypsin ameliorates pristane induced diffuse alveolar hemorrhage in mice","volume":"8","author":"Elshikha","year":"2019","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0710","first-page":"289","article-title":"Alpha-1 antitrypsin therapy for autoimmune disorders","volume":"5","author":"Song","year":"2018","journal-title":"Chronic. Obstr. Pulm Dis."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0715","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091321","article-title":"Regulated hAAT expression from a Novel rAAV vector and its application in the prevention of type 1 diabetes","volume":"8","author":"Ma","year":"2019","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0720","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gt.2015.18","article-title":"beta-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection","volume":"22","author":"El Khatib","year":"2015","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0725","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2337\/db16-0887","article-title":"Mafa enables Pdx1 to effectively convert pancreatic islet progenitors and committed islet alpha-cells into beta-cells in vivo","volume":"66","author":"Matsuoka","year":"2017","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0730","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.stem.2017.11.020","article-title":"Endogenous reprogramming of alpha cells into beta cells, induced by viral gene therapy, reverses autoimmune diabetes","volume":"22","author":"Xiao","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2025.117332_b0735","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1091757","article-title":"PDX1 is the cornerstone of pancreatic \u03b2-cell functions and identity","volume":"9","author":"Ebrahim","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0740","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098283","article-title":"Pax4 in health and diabetes","volume":"24","author":"Ko","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0745","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13287-017-0694-z","article-title":"PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration","volume":"8","author":"Zhu","year":"2017","journal-title":"Stem. Cell Res. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0750","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00125-011-2070-3","article-title":"In vivo genetic engineering of murine pancreatic beta cells mediated by single-stranded adeno-associated viral vectors of serotypes 6, 8 and 9","volume":"54","author":"Jimenez","year":"2011","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0755","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11373-007-9159-1","article-title":"Efficient and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus type 8","volume":"14","author":"Cheng","year":"2007","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0760","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2337\/diabetes.55.04.06.db05-0927","article-title":"Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes","volume":"55","author":"Wang","year":"2006","journal-title":"Diabetes"},{"issue":"7\u20138","key":"10.1016\/j.bcp.2025.117332_b0765","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10495-022-01734-z","article-title":"XIAP as a multifaceted molecule in Cellular Signaling","volume":"27","author":"Hanifeh","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.bcp.2025.117332_b0770","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2019.01.013","article-title":"Nanotechnology in cell replacement therapies for type 1 diabetes","volume":"139","author":"Ernst","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0775","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0780","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/09273948.2017.1298822","article-title":"The role of IFN-alpha in experimental and clinical uveitis","volume":"27","author":"Liu","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0785","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019542","article-title":"AAV2-mediated subretinal gene transfer of hIFN-alpha attenuates experimental autoimmune uveoretinitis in mice","volume":"6","author":"Tian","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0790","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037995","article-title":"AAV2-mediated combined subretinal delivery of IFN-alpha and IL-4 reduces the severity of experimental autoimmune uveoretinitis","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0795","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/08830185.2020.1840565","article-title":"IL-27, a pleiotropic cytokine for fine-tuning the immune response in cancer","volume":"40","author":"Beizavi","year":"2021","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b0800","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037773","article-title":"AAV2-mediated subretinal gene transfer of mIL-27p28 attenuates experimental autoimmune uveoretinitis in mice","volume":"7","author":"Shao","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0805","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270972","article-title":"Inhibition of experimental autoimmune uveitis by intravitreal AAV-equine-IL10 gene therapy","volume":"17","author":"Crabtree","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0810","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1089\/hum.2005.16.1037","article-title":"Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis","volume":"16","author":"Smith","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"22","key":"10.1016\/j.bcp.2025.117332_b0815","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/gt.2008.109","article-title":"Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis","volume":"15","author":"Trittibach","year":"2008","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0820","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000281815","article-title":"A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis","volume":"44","author":"Adamus","year":"2010","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.bcp.2025.117332_b0825","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.796054","article-title":"HLA-G: too much or too little? role in cancer and autoimmune disease","volume":"13","author":"Mart\u00edn-Villa","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0830","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.humimm.2016.01.016","article-title":"CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance","volume":"77","author":"Pankratz","year":"2016","journal-title":"Hum. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128759","article-title":"Capsid mutated adeno-associated virus delivered to the anterior chamber results in efficient transduction of trabecular meshwork in mouse and rat","volume":"10","author":"Bogner","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2025.117332_b0840","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073465","article-title":"Therapeutic applications of Adeno-Associated Virus (AAV) gene transfer of HLA-G in the Eye","volume":"23","author":"Gilger","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0845","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/tan.12427","article-title":"New insights into HLA-G mediated tolerance","volume":"84","author":"Amodio","year":"2014","journal-title":"Tissue Antigens"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0850","doi-asserted-by":"crossref","first-page":"19864","DOI":"10.1038\/s41598-019-56462-3","article-title":"AAV-mediated expression of HLA-G1\/5 reduces severity of experimental autoimmune uveitis","volume":"9","author":"Crabtree","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0855","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.4103\/ijo.IJO_3117_20","article-title":"Gene therapy in retinal diseases: a review","volume":"69","author":"Dhurandhar","year":"2021","journal-title":"Indian J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0860","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.62.2.41","article-title":"Characterization of gene therapy associated uveitis following intravitreal adeno-associated virus injection in mice","volume":"62","author":"Tummala","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0865","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122082","article-title":"AAV mediated delivery of myxoma virus M013 Gene protects the retina against autoimmune uveitis","volume":"8","author":"Ridley","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0870","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hum.2014.089","article-title":"Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation","volume":"26","author":"Ildefonso","year":"2015","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0875","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0880","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b0885","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11882-023-01102-0","article-title":"Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches","volume":"23","author":"Vasileiou","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0890","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0895","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b0900","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029637","article-title":"The interleukin (IL)-23\/T helper (Th)17 axis in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"Hiltensperger","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b0905","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s13311-017-0545-8","article-title":"Clinical and histopathological amelioration of experimental autoimmune encephalomyelitis by AAV vectors expressing a soluble interleukin-23 receptor","volume":"14","author":"Miralles","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bcp.2025.117332_b0910","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3389\/fimmu.2017.01258","article-title":"IL-12p35 inhibits neuroinflammation and ameliorates autoimmune encephalomyelitis","volume":"8","author":"Choi","year":"2017","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0915","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0920","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b0925","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.1801462","article-title":"Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-\u03b1","volume":"203","author":"Vasquez","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.117332_b0930","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.omtm.2022.04.011","article-title":"Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways","volume":"25","author":"Zhong","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bcp.2025.117332_b0935","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40-CD40L Dyad in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"Aarts","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117332_b0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119087","article-title":"Recent trends in cancer therapy: a review on the current state of gene delivery","volume":"269","author":"Yahya","year":"2021","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0945","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/med.21338","article-title":"Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures","volume":"35","author":"Sun","year":"2015","journal-title":"Med. Res. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0950","article-title":"Emerging strategies of cancer therapy based on ferroptosis","volume":"30","author":"Shen","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bcp.2025.117332_b0955","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.omto.2022.09.009","article-title":"Adding recombinant AAVs to the cancer therapeutics mix","volume":"27","author":"Mulcrone","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0960","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020427","article-title":"Hepatocellular carcinoma is a natural target for Adeno-Associated Virus (AAV) 2 vectors","volume":"14","author":"Meumann","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b0965","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12020","article-title":"Intracranial AAV-IFN-\u03b2 gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model","volume":"11","author":"GuhaSarkar","year":"2017","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b0970","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ccell.2023.04.010","article-title":"Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma","volume":"41","author":"Ramachandran","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.117332_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108521","article-title":"Potential targeting of the tumor microenvironment to improve cancer virotherapy","volume":"250","author":"Liao","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b0980","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.18632\/aging.101918","article-title":"Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma","volume":"11","author":"Liu","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b0985","first-page":"1667","article-title":"Plasma mannan?binding lectin and MBL?associated serine protease 2 in patients with hepatocellular carcinoma","volume":"37","author":"Li","year":"2017","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.bcp.2025.117332_b0990","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1782728","article-title":"Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma","volume":"2021","author":"Meng","year":"2021","journal-title":"J. Immunol. Res."},{"issue":"624","key":"10.1016\/j.bcp.2025.117332_b0995","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh4456","article-title":"An AAV gene therapy computes over multiple cellular inputs to enable precise targeting of multifocal hepatocellular carcinoma in mice","volume":"13","author":"Angelici","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"suppl_4","key":"10.1016\/j.bcp.2025.117332_b1000","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/neuonc\/nov164","article-title":"Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma","volume":"18","author":"Oberoi","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2025.117332_b1015","article-title":"High-grade glioma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Stupp","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117332_b1020","doi-asserted-by":"crossref","unstructured":"AAV-Mediated Gene Delivery of LIGHT Prolongs Survival in Glioblastoma. Cancer Discovery 13(7) (2023) pp. 1511-1511.","DOI":"10.1158\/2159-8290.CD-RW2023-078"},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b1025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/03008200802147746","article-title":"Decorin-mediated effects in cancer cell biology","volume":"49","author":"Zafiropoulos","year":"2008","journal-title":"Connect. Tissue Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b1030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1349-7006.2002.tb01262.x","article-title":"Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma","volume":"93","author":"Yoshida","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b1035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/cgt.2009.8","article-title":"Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta","volume":"16","author":"Meijer","year":"2009","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cgt.2014.58","article-title":"Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma","volume":"22","author":"Hicks","year":"2015","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1045","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1186\/s12889-025-22881-3","article-title":"The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021","volume":"25","author":"Tang","year":"2025","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b1050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41417-019-0108-8","article-title":"AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma","volume":"27","author":"Yu","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/71517","article-title":"Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1","volume":"6","author":"Jim\u00e9nez","year":"2000","journal-title":"Nat. Med."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2025.117332_b1060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mvr.2007.04.007","article-title":"Thrombospondin-based antiangiogenic therapy","volume":"74","author":"Zhang","year":"2007","journal-title":"Microvasc. Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b1065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/mt.2014.214","article-title":"Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas","volume":"23","author":"Choi","year":"2015","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b1070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9440(10)63319-6","article-title":"Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-\u03b2","volume":"165","author":"Yee","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b1075","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/0008-5472.CAN-08-2940","article-title":"A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR","volume":"69","author":"Ren","year":"2009","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b1080","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020362","article-title":"AAV-Vectored Expression of the vascular normalizing agents 3TSR and Fc3TSR, and the anti-angiogenic bevacizumab extends survival in a murine model of end-stage epithelial ovarian carcinoma","volume":"10","author":"Stegelmeier","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117332_b1085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2019.04.044","article-title":"Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo","volume":"91","author":"Lee","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bcp.2025.117332_b1090","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2019.06.034","article-title":"Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform","volume":"307","author":"Tong","year":"2019","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b1095","first-page":"4718","article-title":"Increased temperature-related adeno-associated virus vectors transduction of ovarian cancer cells - essential signatures of AAV receptor and heat shock proteins","volume":"18","author":"Bie\u0144kowska","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.bcp.2025.117332_b1100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b1105","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1021\/acs.bioconjchem.9b00511","article-title":"A CD33 antigen-targeted AAV6 vector expressing an inducible caspase-9 suicide gene is therapeutic in a xenotransplantation model of acute myeloid leukemia","volume":"30","author":"Khan","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"24","key":"10.1016\/j.bcp.2025.117332_b1110","doi-asserted-by":"crossref","first-page":"13730","DOI":"10.1073\/pnas.1919690117","article-title":"Selective reactivation of STING signaling to target Merkel cell carcinoma","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b1115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b1120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant Adeno-Associated Virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"issue":"20","key":"10.1016\/j.bcp.2025.117332_b1125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011094","article-title":"Molecular engineering of virus tropism","volume":"25","author":"He","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b1130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41551-022-00938-7","article-title":"Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood\u2013brain barrier in rodents and primates","volume":"6","author":"Yao","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b1135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102635","article-title":"Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease","volume":"36","author":"Kantor","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b1145","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkae401","article-title":"rAAV capsid mutants eliminate leaky expression from DNA donor template for homologous recombination","volume":"52","author":"Ling","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117332_b1150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2025.117332_b1155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.bcp.2025.117332_b1160","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1089\/hum.1998.9.13-1929","article-title":"Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy","volume":"9","author":"Yang","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2025.117332_b1165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666666","article-title":"T Cell-mediated immune responses to AAV and AAV vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b1170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bcp.2025.117332_b1175","doi-asserted-by":"crossref","first-page":"7691","DOI":"10.2147\/IJN.S459905","article-title":"Adeno-Associated virus engineering and load strategy for tropism modification, immune evasion and enhanced transgene expression","volume":"19","author":"Zhou","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"19","key":"10.1016\/j.bcp.2025.117332_b1180","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bcp.2025.117332_b1185","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1190","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12967-024-05599-5","article-title":"AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice","volume":"22","author":"Chauhan","year":"2024","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b1195","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13040823","article-title":"Exosome-Modified AAV gene therapy attenuates autoimmune hepatitis via enhanced regulatory T cell targeting and immune modulation","volume":"13","author":"Shao","year":"2025","journal-title":"Microorganisms"},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b1200","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1016\/j.ymthe.2025.05.011","article-title":"Neuron-targeted gene therapy rescues multiple phenotypes of STXBP1-related disorders in mice and is well tolerated in nonhuman primates","volume":"33","author":"Aeran","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2025.117332_b1205","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jconrel.2017.08.005","article-title":"Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion","volume":"262","author":"Chai","year":"2017","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1210","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50515-6","article-title":"The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders","volume":"15","author":"Kantor","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b1215","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1607","article-title":"Optimization strategies and advances in the research and development of AAV\u2010based gene therapy to deliver large transgenes","volume":"14","author":"Kolesnik","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.117332_b1220","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00109-020-02034-2","article-title":"Evolving AAV-delivered therapeutics towards ultimate cures","volume":"99","author":"He","year":"2021","journal-title":"J. Mol. Med. (Berl)"},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b1225","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117332_b1230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.117332_b1235","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64175","article-title":"scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution","volume":"10","author":"\u00d6zt\u00fcrk","year":"2021","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b1240","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/0113816128286593240226060318","article-title":"Machine-learning-guided directed evolution for AAV capsid engineering","volume":"30","author":"Fu","year":"2024","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b1245","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/mt.2008.116","article-title":"AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice","volume":"16","author":"Rehman","year":"2008","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117332_b1250","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/jnr.24183","article-title":"Glial fibrillary acidic protein promoter determines transgene expression in satellite glial cells following intraganglionic adeno-associated virus delivery in adult rats","volume":"96","author":"Xiang","year":"2018","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1255","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","article-title":"Dual-AAV delivering split prime editor system for invivo genome editing","volume":"30","author":"Zhi","year":"2022","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.bcp.2025.117332_b1260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310524","article-title":"Extending AAV packaging cargo through dual co-transduction: efficient protein trans-splicing at low vector doses","volume":"24","author":"Ferreira","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117332_b1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107764","article-title":"Cellular pathways of recombinant adeno-associated virus production for gene therapy","volume":"49","author":"Sha","year":"2021","journal-title":"Biotechnol. Adv."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b1270","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/bit.28402","article-title":"Process economics evaluation and optimization of adeno-associated virus downstream processing","volume":"121","author":"Lyle","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.bcp.2025.117332_b1275","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108433","article-title":"The state of technological advancement to address challenges in the manufacture of rAAV gene therapies","volume":"76","author":"Destro","year":"2024","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bcp.2025.117332_b1280","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.omtm.2023.05.019","article-title":"Mechanistic modeling explains the production dynamics of recombinant adeno-associated virus with the baculovirus expression vector system","volume":"30","author":"Destro","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"8","key":"10.1016\/j.bcp.2025.117332_b1285","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/bit.28495","article-title":"Peptide ligands for the affinity purification of adeno-associated viruses from HEK 293 cell lysates","volume":"120","author":"Chu","year":"2023","journal-title":"Biotechnol. Bioeng."},{"issue":"4","key":"10.1016\/j.bcp.2025.117332_b1290","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2025.117332_b1295","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6807904","article-title":"Genomic designs of rAAVs contribute to pathological changes in the livers and spleens of mice","volume":"2022","author":"Mulcrone","year":"2022","journal-title":"Adv Cell Gene Ther."},{"issue":"11","key":"10.1016\/j.bcp.2025.117332_b1300","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/mt.2012.197","article-title":"Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity","volume":"20","author":"Rosas","year":"2012","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117332_b1305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2025.117332_b1310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia a identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2025.117332_b1315","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.omtm.2021.10.007","article-title":"AAV-mediated gene therapy for galactosialidosis: a long-term safety and efficacy study","volume":"23","author":"Hu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"9","key":"10.1016\/j.bcp.2025.117332_b1320","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.ymthe.2021.08.016","article-title":"Flies in the ointment: AAV vector preparations and tumor risk","volume":"29","author":"Zhang","year":"2021","journal-title":"Mol. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:13:20Z","timestamp":1761455600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225005970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":264,"alternative-id":["S0006295225005970"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117332","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117332"}}